Latest Industry Insights

180 Life Sciences is exploring the use of synthetic cannabidiol (CBD) analogs as a treatment strategy for inflammation and pain, and conducting clinical research focused on repurposing anti-tumor necrosis factor across different fibrotic conditions. Technology Networks recently spoke with Dr James Woody, chief executive officer at 180 Life Sciences, to find out more about the company's research and development pipeline.

In this interview, Dr Andreas Bergmann discusses how the quantification of two pathway-specific biomarkers can support the diagnosis, monitoring and treatment of sepsis patients.

In this industry insights piece, we explore how gene therapies represent a rapidly growing new paradigm — both therapeutically and with respect to how they are managed within the larger scope of healthcare — and how this has wide-ranging impacts on several key areas, including regulation.

To learn more about the ways that antibody tests are being used in the pandemic, Technology Networks spoke to Heather-Read Harper, European Senior Manager for Immunoassay and Clinical Chemistry at Beckman Coulter.

Today, plant alkaloids are attracting notice as novel therapies for conditions involving inflammation, such as metabolic syndrome, autoimmune disease and even for aging, which are often characterized by chronic, low-grade over-activation of the immune system. This piece takes a closer look at the need for novel treatments and the best uses for plant alkaloids.

Technology Networks spoke with Dr Jan Hellemans, CTO and co-founder of CRO Biogazelle, as well as co-author of the MIQE guidelines, to learn why PCR-based technologies are the "workhorse" technologies for the company.

The emergence of SARS-CoV-2 variants has led to concerns over the potential impacts there could be on the effectiveness of diagnostics and other countermeasures. Here, we look at the effects the B.1.1.7 variant may have on diagnostic tests.

2020 was an important year for proteomics. The COVID-19 global pandemic cast a spotlight on the field's clinical utility in the fight against a public health crisis, from which there are many lessons to be drawn that will undoubtedly influence the landscape of the field for years to come. Technology Networks spoke with Rohan Thakur, executive vice president of Life Sciences Mass Spectrometry at Bruker Daltonics, to discuss the current state-of-play in proteomics.

The trillions of microbes contained in the human body are a key element of a personalized approach to treatment; the microbiome influences endocrinology, physiology, and even neurology, and has a crucial role in disease progression. An area in which interest is growing particularly quickly is oncology. To further investigate the link between the microbiome and cancer, we take a closer look at the current landscape of melanoma research.

To find out more about cannabis testing in California and how CannaSafe is working hard to ensure consumers and patients receive contaminant-free and rigorously-tested cannabis, we spoke to their President, Aaron Riley.